In one meta-analysis [27], the VEGFR-TKIs group (cediranib and axitinib) was associated with higher rates of diarrhea, fatigue, hypertension and thrombocytopenia compared with bevacizumab. The gene discussed is KDR; the disease is Thrombocytopenia.